Clavulanate potassium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1984
- First approval year
- 1984
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Clavulanate potassium
- Molecular weight
- 237.25
- Structure (SMILES)
- O=C([O-])[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21.[K+]
- clavulanate potassium component of augmentin
- Clavulanate potassium component of augmentin
- clavulanate potassium component of clavulox
- Clavulanate potassium component of clavulox
- clavulanate potassium component of timentin
- Clavulanate potassium component of timentin
- 4 oxa 1 azabicyclo 3 2 0 heptane 2 carboxylic acid 3 2 hydroxyethylidene 7 oxo monopotassium salt 2r 2 alpha 3z 5 alpha
- 4-OXA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3-(2-HYDROXYETHYLIDENE)-7-OXO-, MONOPOTASSIUM SALT, (2R-(2.ALPHA.,3Z,5.ALPHA.))-
- augmentin component clavulanate potassium
- AUGMENTIN COMPONENT CLAVULANATE POTASSIUM
- brl 14151k
- BRL 14151K
- BRL-14151K
- brl14151k
- BRL14151K
- clavulanate potassium
- Clavulanate potassium
- Clavulanate potassium [GREEN BOOK]
- Clavulanate potassium [ORANGE BOOK]
- Clavulanate potassium [USAN]
- Clavulanate potassium [USP MONOGRAPH]
- Clavulanate potassium [VANDF]
- Clavulanate potassium [WHO-DD]
- clavulanate potassium green book
- clavulanate potassium orange book
- clavulanate potassium usan
- clavulanate potassium usp monograph
- clavulanate potassium vandf
- clavulanate potassium who dd
- CLAVULANIC ACID (AS CLAVULANATE POTASSIUM)
- clavulanic acid as clavulanate potassium
And 12 more, listed on the interactive page.
- CAS registry numbers
- 61177-45-5
- ChEMBL ID
- CHEMBL1003
- InChIKey
- ABVRVIZBZKUTMK-JSYANWSFSA-M
- PubChem compound IDs
- 23665591
- RxNorm IDs (RxCUI)
- 831418
- FDA ingredient codes (UNII)
- Q42OMW3AT8
- Applicant
- US ANTIBIOTICS
- Approval date
- 6 Aug 1984
- Application number
- NDA050575
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Oral
- Parenteral
Mechanisms of action
- Mechanism
- Bacterial beta-lactamase TEM inhibitor
- Action type
- Inhibitor
- Target
- Beta-lactamase TEM
- Protein identifier
- P62593
Open Targets mechanisms
- Mechanism
- Bacterial beta-lactamase TEM inhibitor
- Action type
- Inhibitor
- Target
- Beta-lactamase TEM
- Condition
- Soft Tissue Infections
- Highest recorded phase
- 4
- Subject identifier
- D018461
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Otitis Media
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004992
- Subject identifier
- D010033
- Condition
- Sinusitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Mastitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001034
- Subject identifier
- D008413
- Condition
- Pyelonephritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001141
- Subject identifier
- D011704
- Condition
- Enterobacteriaceae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001313
- Subject identifier
- D004756
- Condition
- Periapical Periodontitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001391
- Subject identifier
- D010485
- Condition
- Sepsis
- Highest recorded phase
- 1
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Tuberculosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
- Condition
- Otitis Media
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0024330
- Subject identifier
- D010033
- Condition
- Respiratory Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0024355
- Subject identifier
- D012141
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0004992
- Condition identifier
- EFO_0007149
- Condition identifier
- EFO_0007486
- Condition identifier
- EFO_1001034
- Condition identifier
- EFO_1001141
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001313
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001391
- Condition identifier
- EFO_1001459
- Condition identifier
- HP_0100806
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002420
- Condition identifier
- MONDO_0005246
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005441
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005961
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0024330
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0024355
- Condition identifier
- MONDO_0024355
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0100338
- Highest recorded phase
- 4
- Event
- acute generalised exanthematous pustulosis
- Reports
- 78
- Reporting signal score
- 145.358
- Event
- acute kidney injury
- Reports
- 183
- Reporting signal score
- 86.379
- Event
- agranulocytosis
- Reports
- 76
- Reporting signal score
- 87.8636
- Event
- anaphylactic shock
- Reports
- 81
- Reporting signal score
- 95.9114
- Event
- bone erosion
- Reports
- 47
- Reporting signal score
- 128.734
- Event
- bronchiectasis
- Reports
- 46
- Reporting signal score
- 92.7468
- Event
- cholestasis
- Reports
- 281
- Reporting signal score
- 660.116
- Event
- cholestatic liver injury
- Reports
- 31
- Reporting signal score
- 79.4552
- Event
- clostridium difficile colitis
- Reports
- 71
- Reporting signal score
- 129.115
- Event
- drug hypersensitivity
- Reports
- 1,171
- Reporting signal score
- 1,986.73
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 162
- Reporting signal score
- 252.054
- Event
- drug-induced liver injury
- Reports
- 105
- Reporting signal score
- 129.151
- Event
- eosinophilia
- Reports
- 105
- Reporting signal score
- 163.482
- Event
- hepatitis
- Reports
- 97
- Reporting signal score
- 115.771
- Event
- hepatitis acute
- Reports
- 42
- Reporting signal score
- 68.228
- Event
- hepatitis cholestatic
- Reports
- 110
- Reporting signal score
- 284.287
- Event
- hepatocellular injury
- Reports
- 234
- Reporting signal score
- 492.257
- Event
- jaundice
- Reports
- 159
- Reporting signal score
- 245.824
- Event
- jaundice cholestatic
- Reports
- 39
- Reporting signal score
- 84.3272
- Event
- liver injury
- Reports
- 62
- Reporting signal score
- 77.7439
- Event
- mixed liver injury
- Reports
- 60
- Reporting signal score
- 177.007
- Event
- pruritus
- Reports
- 237
- Reporting signal score
- 91.1993
- Event
- purpura
- Reports
- 53
- Reporting signal score
- 84.5299
- Event
- rash maculo-papular
- Reports
- 201
- Reporting signal score
- 380.775
- Event
- toxic skin eruption
- Reports
- 104
- Reporting signal score
- 205.324
- NCT00354965
- NCT00716183
- NCT01110408
- NCT01728363
- NCT02630992
- NCT02795949
- NCT03033147
- NCT03174184
- Dose
- 125 mg/31.25 mg per 5 mL suspension, 250 mg/62.5 mg per 5 mL suspension, 500 mg/125 mg tablet, 875 mg/125 mg tablet, 500 mg/57 mg per 5 mL suspension, 200 mg/28.5 mg per 5 mL suspension, 400 mg/57 mg per 5 mL suspension
- How often
- Every 12 hours or every 8 hours
- Do not substitute different strength tablets without guidance
- Take with meals to enhance absorption
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 87.07
- Calculated partition coefficient (ALogP)
- -1.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 15
- Molecular formula
- C8H8KNO5
- Monoisotopic mass
- 237.00395384
- Natural product
- Yes
- 0093-2274
- 0093-2275
- 0093-2277
- 0093-2279
- 0093-8675
- 0143-9249
- 0143-9853
- 0781-1831
- 0781-1852
- 0781-1874
- 0781-1943
- 0781-6102
- 0781-6104
- 0781-6139
- 16714-292
- 16714-293
- 16714-294
- 16714-295
- 16714-296
- 16714-297
- 42571-160
- 42571-161
- 42571-162
- 43063-077
- 43063-377
And 174 more, listed on the interactive page.
- Recorded assays
- 29
- Active assays
- 3
Active assay types
- Confirmatory
- beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
Related records
Trials (40)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects
- A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections
- A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
- A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
- A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections
- A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
- A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
- A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.
- A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
- Acupuncture and Herbal Treatment of Chronic HIV Sinusitis
- Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward
- An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)
- Antibiotic Duration in Post-appendectomy Abscess
- Antibiotic Therapy Versus Appendectomy for Acute Appendicitis
- Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess
- AUGMENTIN 1gm In Skin And Soft Tissue Infection
- AUGMENTIN™ in Dental Infections
- Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit
Approved for (6)
- Infectious otitis media
- Otitis media
- Pneumonia
- Respiratory tract infectious disorder
- Sinusitis
- Urinary tract infection
In development for (4)
- Mastitis Phase 2
- Periapical periodontitis Phase 2
- Pyelonephritis Phase 3
- Tuberculosis Phase 2
Other linked conditions (2)
- Appendicitis
- Tic disorder